Quinze-Vingts National Ophthalmology Hospital
- Address
- lock Available on a paid plan
Eye Diseases
The Quinze-Vingts National Ophthalmology Hospital conducts trials focusing on eye diseases, including inherited retinal dystrophies, macular edema secondary to retinal vein occlusion, and gene‑therapy approaches for rod‑cone dystrophy. These studies aim to test new therapies, improve visual outcomes, and assess safety.
- Inherited retinal dystrophies
- Macular edema secondary to retinal vein occlusion
- Rod-cone dystrophy gene therapy
Patients at the Paris site can participate in cutting‑edge ocular research designed to preserve vision.
Immune System Diseases
Research at the hospital also addresses immune system diseases affecting the eye, such as moderate‑to‑severe thyroid eye disease and steroid‑dependent non‑infectious uveitis. Trials evaluate biologic agents and immunosuppressive regimens to reduce inflammation and improve ocular function.
- Moderate-to-Severe Thyroid Eye Disease
- Non‑infectious intermediate, posterior and pan‑uveitis
These investigations seek to expand therapeutic options for patients with autoimmune ocular conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 6 therapeutic areas and 15 of 51 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 43 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 14 by active trials.
- 1F. Hoffmann-La Roche AG2active
lock +13 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1F. Hoffmann-La Roche AG4trials
lock +10 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Quinze-Vingts National Ophthalmology Hospital
lock Showing 1 of 39 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (22153) Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | Bayer AG | Phase III | Not Recruiting | Sep 2023 | May 2025 |
IMP list
lock Showing 1 of 51 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Adalimumab | 3 | Unknown | 2024-04-25 | 2024-07-01 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.